Patents by Inventor Helen M. Bramlett
Helen M. Bramlett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124570Abstract: The compositions and methods described herein include methods and agents that inhibit inflammasome signaling in a mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s) or other agents. Also described herein are compositions and methods of use thereof for detecting and treating early-stage Alzheimer's disease as well as other inflammatory neurologic conditions.Type: ApplicationFiled: September 8, 2023Publication date: April 18, 2024Applicant: University of MiamiInventors: Juan Pablo De Rivero Vaccari, Robert W. Keane, W. Dalton Deitrich, Helen M. Bramlett
-
Patent number: 11840565Abstract: The compositions and methods described herein include methods and agents that inhibit inflammasome signaling in a mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s) or other agents. Also described herein are compositions and methods of use thereof for treating viral-associated lung inflammation, for example lung inflammation associated with viral infections such as SARS-CoV-2.Type: GrantFiled: November 12, 2021Date of Patent: December 12, 2023Assignee: UNIVERSITY OF MIAMIInventors: Robert W. Keane, W. Dalton Dietrich, Juan Pablo De Rivero Vaccari, Helen M. Bramlett
-
Publication number: 20230296626Abstract: Compositions and methods for detecting components of the inflammasome in a sample from a subject as markers for inflammasome-related diseases or disorders such as multiple sclerosis, stroke, mild cognitive impairment, Alzheimer's disease, age-related macular degeneration, NASH, inflammaging or traumatic brain injury. Methods of using such inflammasome markers to determine prognosis, direct treatment and monitor response to treatment for the subject with an inflammasome-related disease or disorder such as multiple sclerosis, stroke, mild cognitive impairment, Alzheimer's disease, age-related macular degeneration, NASH, inflammaging or traumatic brain injury are also described.Type: ApplicationFiled: April 27, 2021Publication date: September 21, 2023Applicant: University of MiamiInventors: Robert W. Keane, Dalton W. Deitrich, Juan Pablo de Rivero Vaccari, Helen M. Bramlett
-
Publication number: 20220153826Abstract: The compositions and methods described herein include methods and agents that inhibit inflammasome signaling in a mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s) or other agents. Also described herein are compositions and methods of use thereof for treating viral-associated lung inflammation, for example lung inflammation associated with viral infections such as SARS-CoV-2.Type: ApplicationFiled: November 12, 2021Publication date: May 19, 2022Inventors: Robert W. KEANE, W. Dalton DIETRICH, Juan Pablo De Rivero VACCARI, Helen M. BRAMLETT
-
Patent number: 11174307Abstract: The compositions and methods described herein include methods and agents that inhibit inflammasome signaling in a mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s) or other agents. Also described herein are compositions and methods of use thereof for treating viral-associated lung inflammation, for example lung inflammation associated with viral infections such as SARS-CoV-2.Type: GrantFiled: April 23, 2020Date of Patent: November 16, 2021Assignee: UNIVERSITY OF MIAMIInventors: Robert W. Keane, W. Dalton Dietrich, Juan Pablo De Rivero Vaccari, Helen M. Bramlett
-
Publication number: 20210284723Abstract: The compositions and methods described herein include agents that inhibit inflammasome signaling in the mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s). Also described herein are compositions and methods of use thereof for treating inflammasome related diseases or conditions.Type: ApplicationFiled: July 3, 2019Publication date: September 16, 2021Inventors: Robert W. KEANE, W. Dalton DIETRICH, Juan Pablo DE RIVERO VACCARI, Helen M. BRAMLETT, Roberta BRAMBILLA
-
Patent number: 10961306Abstract: The compositions and methods described herein include agents that inhibit inflammasome signaling in the mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s). Also described herein are compositions and methods of use thereof for treating multiple sclerosis.Type: GrantFiled: April 13, 2020Date of Patent: March 30, 2021Assignee: UNIVERSITY OF MIAMIInventors: Robert W. Keane, W. Dalton Dietrich, Juan Pablo De Rivero Vaccari, Helen M. Bramlett, Roberta Brambilla
-
Publication number: 20200354442Abstract: Compositions and methods for reducing inflammation in the central nervous system (CNS) of a mammal that has been subjected to a stroke, traumatic injury to the CNS such as traumatic brain injury (TBI), spinal cord injury (SCI), or having an autoimmune or CNS disease have been developed. The compositions and methods described herein include antibodies that specifically bind to at least one component (e.g., ASC, NALP1) in a mammalian inflammasome (e.g., the NALP1 inflammasome) and have use as treatments for SCI, TBI, stroke, and autoimmune and CNS diseases in a mammal. In a rodent model of SCI, therapeutic neutralization of ASC using a polyclonal antibody that specifically binds to ASC inhibited the inflammasome, reduced caspase-1 activation, XIAP cleavage, and interleukin processing, resulting in significant tissue sparing and functional improvement. Additionally, in a rodent model of TBI, neutralization of ASC after TBI reduced caspase-1 activation and XIAP cleavage.Type: ApplicationFiled: July 31, 2020Publication date: November 12, 2020Inventors: Robert W. KEANE, W. Dalton DIETRICH, Juan Pablo De Rivero VACCARI, Helen M. BRAMLETT
-
Publication number: 20200347124Abstract: The compositions and methods described herein include agents that inhibit inflammasome signaling in the mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s). Also described herein are compositions and methods of use thereof for treating multiple sclerosis.Type: ApplicationFiled: April 13, 2020Publication date: November 5, 2020Inventors: Robert W. KEANE, W. Dalton DIETRICH, Juan Pablo De Rivero VACCARI, Helen M. Bramlett, Roberta Brambilla
-
Publication number: 20200308262Abstract: The compositions and methods described herein include methods and agents that inhibit inflammasome signaling in a mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s) or other agents. Also described herein are compositions and methods of use thereof for treating viral-associated lung inflammation, for example lung inflammation associated with viral infections such as SARS-CoV-2.Type: ApplicationFiled: April 23, 2020Publication date: October 1, 2020Inventors: Robert W. KEANE, W. Dalton DIETRICH, Juan Pablo De Rivero VACCARI, Roberta BRAMBILLA, Helen M. BRAMLETT
-
Patent number: 10703811Abstract: The compositions and methods described herein include agents that inhibit inflammasome signaling in the mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s). Also described herein are compositions and methods of use thereof for treating multiple sclerosis.Type: GrantFiled: July 3, 2018Date of Patent: July 7, 2020Assignee: UNIVERSITY OF MIAMIInventors: Robert W. Keane, W. Dalton Dietrich, Juan Pablo De Rivero Vaccari, Helen M. Bramlett, Roberta Brambilla
-
Publication number: 20190002550Abstract: The compositions and methods described herein include agents that inhibit inflammasome signaling in the mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s). Also described herein are compositions and methods of use thereof for treating multiple sclerosis.Type: ApplicationFiled: July 3, 2018Publication date: January 3, 2019Inventors: Robert W. Keane, W. Dalton Dietrich, Juan Pablo De Rivero Vaccari, Helen M. Bramlett, Roberta BRAMBILLA
-
Publication number: 20170107277Abstract: Compositions and methods for reducing inflammation in the central nervous system (CNS) of a mammal that has been subjected to a stroke, traumatic injury to the CNS such as traumatic brain injury (TBI), spinal cord injury (SCI), or having an autoimmune or CNS disease have been developed. The compositions and methods described herein include antibodies that specifically bind to at least one component (e.g., ASC, NALP1) in a mammalian inflammasome (e.g., the NALP1 inflammasome) and have use as treatments for SCI, TBI, stroke, and autoimmune and CNS diseases in a mammal. In a rodent model of SCI, therapeutic neutralization of ASC using a polyclonal antibody that specifically binds to ASC inhibited the inflammasome, reduced caspase-1 activation, XIAP cleavage, and interleukin processing, resulting in significant tissue sparing and functional improvement. Additionally, in a rodent model of TBI, neutralization of ASC after TBI reduced caspase-1 activation and XIAP cleavage.Type: ApplicationFiled: October 28, 2016Publication date: April 20, 2017Inventors: Robert W. KEANE, W. Dalton DIETRICH, Juan Pablo DE RIVERO VACCARI, Helen M. BRAMLETT
-
Patent number: 9512209Abstract: Compositions and methods for reducing inflammation in the central nervous system (CNS) of a mammal that has been subjected to a stroke, traumatic injury to the CNS such as traumatic brain injury (TBI), spinal cord injury (SCI), or having an autoimmune or CNS disease have been developed. The compositions and methods described herein include antibodies that specifically bind to at least one component (e.g., ASC, NALP1) in a mammalian inflammasome (e.g., the NALP1 inflammasome) and have use as treatments for SCI, TBI, stroke, and autoimmune and CNS diseases in a mammal. In a rodent model of SCI, therapeutic neutralization of ASC using a polyclonal antibody that specifically binds to ASC inhibited the inflammasome, reduced caspase-1 activation, XIAP cleavage, and interleukin processing, resulting in significant tissue sparing and functional improvement. Additionally, in a rodent model of TBI, neutralization of ASC after TBI reduced caspase-1 activation and XIAP cleavage.Type: GrantFiled: March 19, 2014Date of Patent: December 6, 2016Assignee: University of MiamiInventors: Robert W. Keane, W. Dalton Dietrich, Juan Pablo De Rivero Vaccari, Helen M. Bramlett
-
Publication number: 20140286956Abstract: Compositions and methods for reducing inflammation in the central nervous system (CNS) of a mammal that has been subjected to a stroke, traumatic injury to the CNS such as traumatic brain injury (TBI), spinal cord injury (SCI), or having an autoimmune or CNS disease have been developed. The compositions and methods described herein include antibodies that specifically bind to at least one component (e.g., ASC, NALP1) in a mammalian inflammasome (e.g., the NALP1 inflammasome) and have use as treatments for SCI, TBI, stroke, and autoimmune and CNS diseases in a mammal. In a rodent model of SCI, therapeutic neutralization of ASC using a polyclonal antibody that specifically binds to ASC inhibited the inflammasome, reduced caspase-1 activation, XIAP cleavage, and interleukin processing, resulting in significant tissue sparing and functional improvement. Additionally, in a rodent model of TBI, neutralization of ASC after TBI reduced caspase-1 activation and XIAP cleavage.Type: ApplicationFiled: March 19, 2014Publication date: September 25, 2014Applicant: University of MiamiInventors: Robert W. KEANE, W. Dalton Dietrich, Juan Pablo De Rivero Vaccari, Helen M. Bramlett
-
Patent number: 8685400Abstract: Compositions and methods for reducing inflammation in the central nervous system (CNS) of a mammal that has been subjected to a stroke, traumatic injury to the CNS such as traumatic brain injury (TBI), spinal cord injury (SCI), or having an autoimmune or CNS disease have been developed. The compositions and methods described herein include antibodies that specifically bind to at least one component (e.g., ASC, NALP1) in a mammalian inflammasome (e.g., the NALP1 inflammasome) and have use as treatments for SCI, TBI, stroke, and autoimmune and CNS diseases in a mammal. In a rodent model of SCI, therapeutic neutralization of ASC using a polyclonal antibody that specifically binds to ASC inhibited the inflammasome, reduced caspase-1 activation, XIAP cleavage, and interleukin processing, resulting in significant tissue sparing and functional improvement. Additionally, in a rodent model of TBI, neutralization of ASC after TBI reduced caspase-1 activation and XIAP cleavage.Type: GrantFiled: July 30, 2008Date of Patent: April 1, 2014Assignee: University of MiamiInventors: Robert W. Keane, W. Dalton Dietrich, Juan Pablo De Rivero Vaccari, Helen M. Bramlett
-
Publication number: 20090104200Abstract: Compositions and methods for reducing inflammation in the central nervous system (CNS) of a mammal that has been subjected to a stroke, traumatic injury to the CNS such as traumatic brain injury (TBI), spinal cord injury (SCI), or having an autoimmune or CNS disease have been developed. The compositions and methods described herein include antibodies that specifically bind to at least one component (e.g., ASC, NALP1) in a mammalian inflammasome (e.g., the NALP1 inflammasome) and have use as treatments for SCI, TBI, stroke, and autoimmune and CNS diseases in a mammal. In a rodent model of SCI, therapeutic neutralization of ASC using a polyclonal antibody that specifically binds to ASC inhibited the inflammasome, reduced caspase-1 activation, XIAP cleavage, and interleukin processing, resulting in significant tissue sparing and functional improvement. Additionally, in a rodent model of TBI, neutralization of ASC after TBI reduced caspase-1 activation and XIAP cleavage.Type: ApplicationFiled: July 30, 2008Publication date: April 23, 2009Applicant: UNIVERSITY OF MIAMIInventors: ROBERT W. KEANE, W. Dalton Dietrich, Juan Pablo De Rivero Vaccari, Helen M. Bramlett